BARDA seeks 2-PAM autoinjectors for nerve agent antidote stockpile.
The Biomedical Advanced Research and Development Authority (BARDA), under the Department of Health and Human Services, is soliciting proposals for the procurement of 2-PAM Autoinjectors for Project Bioshield. The requirement involves the supply of autoinjectors containing pralidoxime chloride (2-PAM), used as an antidote for nerve agent poisoning. The contract will support the Strategic National Stockpile. Offerors must demonstrate capability to manufacture FDA-approved autoinjectors and meet strict quality and delivery timelines. The contract value is estimated to exceed $10 million based on the scale of Project Bioshield procurements.